Eli Lilly Achieves $1 Trillion Market Value Amid Weight-Loss Drug Surge

On November 21, 2025, Eli Lilly (LLY.N) became the first healthcare company to reach a market capitalization of $1 trillion, joining an exclusive group typically dominated by technology firms. This milestone highlights the company's significant growth driven by the booming demand for its weight-loss drugs, particularly Mounjaro and Zepbound. The stock price surged over 35% this year, reflecting investor confidence in the future of obesity treatments. In the latest quarter, Eli Lilly reported over $10.09 billion in revenue from its obesity and diabetes portfolio, accounting for more than half of its total revenue of $17.6 billion.

ReutersCNBC

The weight-loss drug market has transformed into one of the most lucrative segments in healthcare, with projections estimating its worth to reach $150 billion by 2030. Eli Lilly's Mounjaro generated $6.52 billion in revenue in the third quarter of 2025, marking a 109% increase from the previous year, while Zepbound saw a remarkable 184% spike, bringing in $3.59 billion. Analysts predict that the demand for these treatments will continue to grow as approvals for their use and insurance coverage expand. Additionally, Eli Lilly is set to introduce an oral version of its obesity drug, orforglipron, expected to be approved early next year.

CNBC

Eli Lilly's rise has come at the expense of its chief rival, Novo Nordisk (NOVOb.CO), which initially led the GLP-1 drug market. However, Eli Lilly has eclipsed Novo Nordisk in prescriptions, positioning itself as a dominant player. Despite this, Novo Nordisk remains a formidable competitor, recently engaging in a $10 billion bidding war for obesity drugmaker Metsera against Pfizer. Analysts are closely monitoring whether Eli Lilly can sustain its growth amidst potential pricing pressures on Mounjaro and Zepbound.

CNBCReuters

Kevin Gade, chief operating officer at Bahl and Gaynor, remarked, "Lilly joins a coveted trillion-dollar market cap group as the investment public begins to fully appreciate the robust innovation Eli Lilly has given to patients." Citi analysts noted that the latest generation of GLP-1 drugs has been a "sales phenomenon," and orforglipron is poised to benefit from the groundwork laid by its injectable predecessors.

Reuters

Despite the positive outlook, some analysts express caution regarding Eli Lilly's ability to maintain its growth trajectory. Concerns have been raised about the potential impact of pricing pressures on its leading drugs and whether the company's expansion plans will effectively counteract margin pressures.

CNBC

• “Lilly joins a coveted trillion-dollar market cap group as the investment public begins to fully appreciate the robust innovation Eli Lilly has given to patients,” — Kevin Gade, Chief Operating Officer, Bahl and Gaynor

Reuters

Eli Lilly's achievement marks a significant moment in the pharmaceutical industry, reflecting the growing importance of weight-loss treatments in healthcare and the company's strategic positioning within this rapidly expanding market.

CNBC